Pharmaceutical

(Curcumin + doxorubicin) by Immix BioPharma for Colorectal Cancer: Likelihood of Approval

(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Colorectal Cancer.

Dec 24, 2023 - 18:00
(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Colorectal Cancer.
Read the original article

Tags:

Previous Article

(Curcumin + doxorubicin) by Immix BioPharma for Metastatic Colorectal Cancer: Li...

Next Article

Enzalutamide by Pfizer for Peritoneal Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ANeuroTech shares plans for major depressive disorder pivotal programme

ANeuroTech shares plans for major depressive disorder p...

Jun 17, 2023

Revised EU/Pfizer/BioNTech Covid-19 vaccine deal may lead to a Comirnaty monopoly

Revised EU/Pfizer/BioNTech Covid-19 vaccine deal may le...

Jun 3, 2023

UK clinical trials industry tackles recent changes in the sector

UK clinical trials industry tackles recent changes in t...

May 21, 2024